Ab­b­Vie is gun­ning for ac­cel­er­at­ed ap­proval of an­ti­body-drug con­ju­gate af­ter pos­i­tive PhII da­ta

Ab­b­Vie plans to ex­plore ac­cel­er­at­ed ap­proval for its an­ti­body-drug con­ju­gate as a monother­a­py in non-small cell lung can­cer fol­low­ing pos­i­tive Phase II topline da­ta. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER